

Fig. 1A




Fig. 1B




Fig. 1C




Fig. 1D




Fig. 1E




Fig. 1F




Fig. 1G




Fig. 1H




Fig. 11




Fig. 1K




Fig. 1L




Fig. 1M




Fig. 1N




Fig. 1P




Fig. 1Q




Fig. 1R






Fig. 15






Fig. 17

Fig. 1U





Fig. 1V






Fig. 2A

Fig. 2B




Fig. 2C




FIG. 3




FIG. 4




FIG. 5




FIG. 6




FIGURE 7




FIG. 8




FIG. 9




Fig. 10

Conformational Equilibrium of
Xaa-boroProline Inhibitors




Fig. 11






Fig. 11B:



(KbP)2 EGS Costimulation
IL-2 production by OKT3 stimulated H9 cells




Fig. 12

(KbP)₂EGS

EGS: Ethylene glycolbis(succinimidylsuccinate)




FIG. 13